Postoperative Nausea and Vomiting, Sex Hormone, Transgender
Conditions
Keywords
Postoperative nausea and vomiting, sex hormone, estrogen, testosterone, transgender
Brief summary
This study aims to investigate the rates of postoperative nausea and vomiting in transgender patients on hormone therapy compared to cisgender patients undergoing the same procedures (hysterectomy, orchiectomy, augmentation mammoplasty).
Detailed description
A retrospective cohort study will be performed using the TriNetX database. Cohorts were defined using Common Procedural Terminology and International Classification of Diseases-10 codes. Separate analyses will be performed for hysterectomies, orchiectomies, and augmentation mammoplasties. Patients will be excluded if they had a history of postoperative nausea and vomiting or a history of neoplasm for which the respective procedure would be indicated (e.g., uterine, cervical, testicular, or breast cancer). Transgender patients will be excluded if not on exogenous hormone therapy and cisgender patients will be excluded if on the same exogenous hormone therapy as their transgender counterparts. Patients will be divided into two groups (transgender group and cisgender group) based on whether they had a diagnosis of sex reassignment, transsexualism, or gender identity disorder. The cohorts will be propensity score-matched based on age, race/ethnicity, and tobacco use.
Interventions
PROCEDUREOrchiectomy
CPT:54520
PROCEDUREHysterectomy
CPT:1013911
PROCEDUREAugmentation mammoplasty
CPT:19325
Sponsors
Riverside University Health System Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Hysterectomy Cohort: Inclusion: \- Patients who underwent hysterectomies. Exclusion: \- Patients who had malignant neoplasm of the uterus, ovarian, cervical, endometrium, or adnexa. Transgender Male Group Inclusion: * administered testosterone within 6 months and 1 day before their hysterectomy * have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism. Cisgender Female Group Inclusion: \- identified as female. Exclusion: * administered testosterone within 6 months and 1 day before their hysterectomy * have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism. Orchiectomy Cohort: Inclusion: \- patients underwent an orchiectomy. Exclusion: \- history of malignant neoplasm of the testis, malignant neoplasm of the prostate, Fournier gangrene, or vascular disorders of male genital organs Transgender Female Group Inclusion: * administered estrogen within 6 months and 1 day before their orchiectomy * have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism. Cisgender Male Group Inclusion: \- identified as male. Exclusion: * administered estrogen within 6 months and 1 day before their orchiectomy * have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism. Augmentation Mammoplasty: Inclusion: \- underwent augmentation mammoplasties. Exclusion: \- Have diagnosis of malignant neoplasm of the breast . Transgender Female Group Inclusion: * administered estrogen within 6 months and 1 day before their augmentation mammoplasty * have one of the following diagnoses: personal history of sex reassignment, gender identity disorder, or transsexualism. Cisgender Female Group Inclusion: \- Identified as female Exclusion: * administered estrogen within 6 months and 1 day before their hysterectomy * have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rescue antiemetics | Within 24 hours of surgery | The primary outcome will be the administration of a rescue antiemetic within 24 hours of surgery. Rescue antiemetics will include droperidol, promethazine, dimenhydrinate, metoclopramide, and prochlorperazine based on rescue antiemetics from the Fourth Consensus PONV Guidelines. |
Countries
United States
Outcome results
None listed